Zobrazeno 1 - 9
of 9
pro vyhledávání: '"bicalutamid"'
DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 34-37 (2016)
Prostate cancer (PCa) is a hormonsensitive tumor. Due to the discovery of the androgen receptor (AR) it became possible to implement the antiandrogens as drugs blocking testosterone Binding to the AR into routine clinical practice. There have been di
Externí odkaz:
https://doaj.org/article/ccc336ae36df4d01be13a8184eb76018
Autor:
Wirth, Manfred, Fröhner, Michael
Publikováno v:
Eur Urol 1999;36(suppl 2):14–19, ISSN: 0302-2838
There is increasing interest in the use of adjuvant hormonal therapies, which are given after the resection or destruction of all gross disease, in early-stage prostate cancer, as a significant proportion of patients experience progression and/or die
Externí odkaz:
https://tud.qucosa.de/id/qucosa%3A27593
https://tud.qucosa.de/api/qucosa%3A27593/attachment/ATT-0/
https://tud.qucosa.de/api/qucosa%3A27593/attachment/ATT-0/
Autor:
Wirth, Manfred
Publikováno v:
Eur Urol 2001;40(suppl 2):17–23, ISSN: 0302-2838
The advent of prostate-specific antigen (PSA) testing and increased patient awareness has led to patients being diagnosed with prostate cancer at an earlier stage and a younger age than previously. Adjuvant hormonal therapy to radiotherapy or prostat
Externí odkaz:
https://tud.qucosa.de/id/qucosa%3A27591
https://tud.qucosa.de/api/qucosa%3A27591/attachment/ATT-0/
https://tud.qucosa.de/api/qucosa%3A27591/attachment/ATT-0/
Autor:
Wirth, Manfred P., Fröhner, Michael
Publikováno v:
Oncology 2003;65(suppl 1):1–4, ISSN: 0030-2414
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam
Externí odkaz:
https://tud.qucosa.de/id/qucosa%3A27515
https://tud.qucosa.de/api/qucosa%3A27515/attachment/ATT-0/
https://tud.qucosa.de/api/qucosa%3A27515/attachment/ATT-0/
Autor:
Manfred P. Wirth
Publikováno v:
Eur Urol 2001;40(suppl 2):17–23, ISSN: 0302-2838
The advent of prostate-specific antigen (PSA) testing and increased patient awareness has led to patients being diagnosed with prostate cancer at an earlier stage and a younger age than previously. Adjuvant hormonal therapy to radiotherapy or prostat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46d7af4e1270e159a809b3bfd2794dc4
https://doi.org/10.1159/000049880
https://doi.org/10.1159/000049880
Publikováno v:
Journal für Urologie und Urogynäkologie, Vol 16, Iss 3, Pp 9-11 (2009)
Einleitung: Androgendeprivationstherapie mit LH-RH-Agonisten bzw. Androgenrezeptorblockade mit Bicalutamid wurde zur Standardtherapie beim fortgeschrittenen Prostatakarzinom. Der Großteil der existierenden Literatur beschreibt unter LH-RH-Gabe und d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::f78b27ad280bc84b0e6fdf92da5b5d5c
http://www.kup.at/kup/pdf/8121.pdf
http://www.kup.at/kup/pdf/8121.pdf
Autor:
Somay C
Publikováno v:
Journal für Urologie und Urogynäkologie, Vol 14, Iss 2, Pp 20-22 (2007)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::e33987348e367281285dececb9c48597
http://www.kup.at/kup/pdf/6541.pdf
http://www.kup.at/kup/pdf/6541.pdf
Autor:
Wirth, Manfred P., Fröhner, Michael
Publikováno v:
Oncology 2003;65(suppl 1):1–4, ISSN: 0030-2414
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4179::e8463fef562c45f7e7ca741f448d8e28
https://tud.qucosa.de/id/qucosa:27515
https://tud.qucosa.de/id/qucosa:27515
Autor:
M. Froehner, Manfred P. Wirth
Publikováno v:
Eur Urol 1999;36(suppl 2):14–19, ISSN: 0302-2838
There is increasing interest in the use of adjuvant hormonal therapies, which are given after the resection or destruction of all gross disease, in early-stage prostate cancer, as a significant proportion of patients experience progression and/or die
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5f02f3da83e25a3a1765df4a4369a4
https://tud.qucosa.de/id/qucosa:27593
https://tud.qucosa.de/id/qucosa:27593